Recombinant multi-species BCR protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCR protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
A reciprocal translocation between chromosomes 22 and 9 produces the Philadelphia chromosome, which is often found in patients with chronic myelogenous leukemia. The chromosome 22 breakpoint for this translocation is located within the BCR gene. The translocation produces a fusion protein which is encoded by sequence from both BCR and ABL, the gene at the chromosome 9 breakpoint. Although the BCR-ABL fusion protein has been extensively studied, the function of the normal BCR gene product is not clear. The unregulated tyrosine kinase activity of BCR-ABL1 contributes to the immortality of leukaemic cells. The BCR protein has serine/threonine kinase activity and is a GTPase-activating protein for p21rac and other kinases. Two transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jan 2020]
The Alternative Names of target: 5133400C09Rik,ALL,BCR,BCR1,Bcr,Breakpoint cluster region protein,CML,D22S11,D22S662,PHL,Renal carcinoma antigen NY-REN-26,mKIAA3017

Target products collectionGo to BCR products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP10961-Ag-1/ GM-Tg-hg-IP10961-Ag-2 Human BCR protein Human
GM-Tg-rg-IP10961-Ag-1/ GM-Tg-rg-IP10961-Ag-2 Rat BCR protein Rat
GM-Tg-mg-IP10961-Ag-1/ GM-Tg-mg-IP10961-Ag-2 Mouse BCR protein Mouse
GM-Tg-cynog-IP10961-Ag-1/ GM-Tg-cynog-IP10961-Ag-2 Cynomolgus/Rhesus macaque BCR protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP10961-Ag-1/ GM-Tg-felg-IP10961-Ag-2 Feline BCR protein Feline
GM-Tg-cang-IP10961-Ag-1/ GM-Tg-cang-IP10961-Ag-2 Canine BCR protein Canine
GM-Tg-bovg-IP10961-Ag-1/ GM-Tg-bovg-IP10961-Ag-2 Bovine BCR protein Bovine
GM-Tg-equg-IP10961-Ag-1/ GM-Tg-equg-IP10961-Ag-2 Equine BCR protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP10961-Ag-1/ GM-Tg-hg-IP10961-Ag-2; GM-Tg-rg-IP10961-Ag-1/ GM-Tg-rg-IP10961-Ag-2;
GM-Tg-mg-IP10961-Ag-1/ GM-Tg-mg-IP10961-Ag-2; GM-Tg-cynog-IP10961-Ag-1/ GM-Tg-cynog-IP10961-Ag-2;
GM-Tg-felg-IP10961-Ag-1/ GM-Tg-felg-IP10961-Ag-2; GM-Tg-cang-IP10961-Ag-1/ GM-Tg-cang-IP10961-Ag-2;
GM-Tg-bovg-IP10961-Ag-1/ GM-Tg-bovg-IP10961-Ag-2; GM-Tg-equg-IP10961-Ag-1/ GM-Tg-equg-IP10961-Ag-2
Products Name BCR protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name BCR
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine BCR protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.